Dyadic International (DYAI) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Nov, 2026Executive summary
First direct commercial sales of recombinant transferrin and DNase I established a new product revenue channel, though initial sales were not material; partner launches and distribution also advanced.
Commercialization remains slower than planned as customer qualification takes longer, while strategy emphasizes partnerships, licensing and supply agreements to scale with less capital investment.
C1 biopharma programs advanced into preclinical animal studies, but substantial doubt about the ability to continue as a going concern and constrained financing remain central concerns.
Financial highlights
Q3 revenue was $449,101, down 61.4% YoY from $1.16 million, primarily due to lower grant and R&D collaboration revenue; 9M revenue was $2.52 million, essentially flat YoY.
Q3 revenue comprised $276,372 in grants, $162,318 in R&D revenue and $10,411 in license and milestone revenue; 9M grant revenue was $1.60 million.
Q3 operating loss was $1.81 million versus $1.93 million; net loss was $1.36 million, or $0.04/share, versus $1.98 million, or $0.06/share.
9M operating loss was $5.77 million versus $5.66 million; net loss was $5.44 million, or $0.15/share, versus $5.80 million, or $0.18/share.
Q3 cost of revenue fell 63.4% to $375,115; internal R&D expense fell 24.8% to $429,945 and G&A fell 2.1% to $1.45 million.
Outlook and guidance
The $225,000 Inzymes milestone for the October commercial sale of Dapibus-produced camel chymosin is expected to be recognized as Q4 2026 revenue.
Gates-funded RSV and malaria antibody animal-study results are expected in Q1 2027; further development depends on results and external funding.
Management expects operating losses and negative operating cash flows to continue; unrestricted cash, cash equivalents and investments, net of unpaid offering costs, were expected to fund operations for seven months at the 9M cash-use rate.
Financing, grant funding, expanded product sales, licensing, partnerships and supply arrangements are being pursued, with execution and timing uncertain.
Latest events from Dyadic International
- Commercial-stage products and partnerships drive growth in life sciences and beyond.DYAI
Lytham Partners Fall 2026 Investor Conference - Commercial execution underway with growing product sales and key partnerships driving near-term growth.DYAI
IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 - Biotech firm registers 3.6M shares for resale via warrants, proceeds fund growth and R&D.DYAI
Registration filing - Commercial-stage protein platform drives growth with new products, partners, and recurring revenues.DYAI
Q3 Investor Summit Group Virtual Conference 2026 - Scalable, animal-free protein platforms deliver rapid, high-yield solutions for global biologics markets.DYAI
Corporate presentation - Flat Q2 revenue, higher costs, and cash burn widened losses and increased going concern risk.DYAI
Q2 2026 - Shifted to commercial focus with new product launches, wider net loss, and strong liquidity.DYAI
Q3 2025 - Q3 2024 revenue rose 393% to $1.96M, net loss narrowed, and cash reached $10M.DYAI
Q3 2024 - Revenue up 18% on grants; product launches and strong liquidity expected in 2025.DYAI
Q1 2025